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AnumberofBruton’styrosinekinase(BTK)inhibitorsarecurrentlyindevelopment,yetithasbeendifficult
to visualize BTK expression and pharmacological inhibition in vivo in real time. We synthesized a
fluorescent, irreversible BTK binder based on the drug Ibrutinib and characterized its behavior in cells and
in vivo. We show a 200 nM affinity of the imaging agent, high selectivity, and irreversible binding to its
target following initial washout, resulting in surprisingly high target-to-background ratios. In vivo, the
imagingagentrapidlydistributedtoBTKexpressingtumorcells,butalsotoBTK-positivetumor-associated
host cells.
B
ruton’s tyrosine kinase (BTK) is a non-receptor tyrosine kinase with restricted cellular expression largely
limitedtoBlymphocytes,macrophages/monocytes,andcertaincancercells
1–4.Asacriticalcomponentofthe
B cell receptor (BCR) signaling network, BTK is crucial for B cell development
5,6 and acts in multiple anti-
apoptotic signaling pathways, including the PI3K-AKT
7, STAT5
8 and NF-kB
9,10pathways. BTK is thus intimately
involvedinregulatingcellsurvival,proliferation,anddifferentiation.Inhumanhaematologicalmalignancies,BTK
is abundantly expressed and activated in malignant cells from patients with B-cell multiple myeloma
11, acute
myeloid leukemia (AML)
12, chronic lymphocytic leukemia (CLL)
13, and non-Hodgkin’s lymphoma (NHL)
14,15.
It is thus estimated that there are about 80,000 new BTK-positive haematologic malignancies in the US per year.
Several BTK inhibitors are under development and have shown remarkable efficacy in early clinical trials
16–20.
Ibrutinib (PCI-32765) is one example of a selective, irreversible BTK inhibitor, whose covalent binding results in
long-lasting target occupancy, retaining inhibitory effect until new protein is synthesized
21,22. The irreversible
inhibitory effectofIbrutinib isattributed toanelectrophilic group onthemolecule bindingcovalently toCys481
intheactivesiteofBTK
23.MostclinicaltrialstodatehavereliedoninsensitivestandardizedResponseEvaluation
Criteria approaches, such as computed tomography (CT), to image drug effects, while a denaturing gel electro-
phoresis assay has been used when tissue is available in Ibrutinib trials
21,24. In the latter assay, a fluorescent probe
bindsanyunoccupiedBTKintissuebiopsyorbloodtoproduceafluorescentband;thelightertheband,themore
BTK is occupied bydrug. Even in co-clinical trialsusing mouse models, drug efficacy is largelytested by volumetrics
orcellcounts,whilelittleisknownaboutthekineticsofdrugdistributioninvivo,accumulation acrosscelltypes,and
their respective heterogeneities or drug effects. There is therefore a need for imaging tools to study BTK inhibitor
distribution at thesingle cell level in vivo. Such tools could bevaluable to better understand kinetics, selectivity, drug
action, inform on dose ranging studies, and allow in vitro testing of harvested cells from patients. Furthermore,
imaging would be especially useful in the development of next generation BTK inhibitors
19,25,26.
WehypothesizedthatanIbrutinib-likescaffoldcouldbeconvertedintoacompaniondiagnosticimagingagent
by modification with a fluorescent tag while preserving irreversible target binding. The goal of the current study
was to explore whether terminal modification of Ibrutinib could generate a BTK-selective imaging agent for in
vivo use. Given the irreversible nature of target binding, one would expect improved target-to-background ratios
followingtheclearanceofunbound fractions.Weindeedshowremarkable targetlocalization,specificity, andthe
ability to measure drug distribution and target inhibition in vivo. As more attention is paid to cell-to-cell
heterogeneity in drug response and its impact on efficacy, we believe this will be a useful tool to study BTK
expression and inhibition
27.
Results
We sought to design a bright, fluorescent derivative of an irreversible BTK inhibitor that would preserve the
selectivity of the parent drug. As such a model agent, Ibrutinib fits tightly into the ATP binding pocket of BTK,
forms an irreversible bond with Cys481, and has a suitable modification point for fluorochrome attachment
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SCIENTIFIC REPORTS | 4 : 4782 | DOI: 10.1038/srep04782 1(PDB: 3GEN, Fig. 1a). A BODIPY-FL modified Ibrutinib (Ibrutinib-
BFL) was designed and synthesized de novo in seven steps (Fig. 1b).
Briefly, iodination of commercially available pyrazolopyrimidine
compound with N-Iodosuccinimide, followed by Suzuki coupling
of the product with 4-phenyloxybenzene boronic acid, resulted in
compound 2. Mitsunobu reaction of compound 2 with N-Boc-3-
hydroxypiperidine resulted in compound 3. After deprotection of
the Boc protecting group in acidic conditions, the crude product
was coupled with the linker (compound 5) to introduce a Michael
acceptor for the irreversible binding affinity. Coupling of the crude
Boc-deprotected compound 6 with BODIPY-FL-NHS finalized the
synthetic steps to produce Ibrutinib-BFL (7) at an overall yield of
,11%.
To confirm the effect of BFL modification on the inhibition effi-
cacy of the drug, half-maximal inhibitory concentration (IC50)o f
Ibrutinib and Ibrutinib-BFL were determined against purified BTK
enzyme.Ibrutinib-BFLhadanIC50of,200 nM,whichislesspotent
than the parent drug (,2n MI C 50; data not shown). Although it
may be possible to further optimize the affinity of Ibrutinib-BFL by
testing various linkers, we found the current generation probe to be
quite acceptable for imaging, as shown in subsequent experiments.
We next determined whether Ibrutinib-BFL would bind to purified
BTK in vitro, endogenous BTK in live cells, and ultimately in vivo.
Purified BTK was incubated with varying concentrations of the
imaging probe for one hour at room temperature, denatured at
70uC for 10 minutes and then processed for SDS-PAGE gel analysis.
There was a clear dose-response increase of the fluorescent signal
around 80 kDa (BTK molecular weight is 76 kDa), as well as at the
bottom of the gel (unbound fraction of Ibrutinib-BFL) (Fig. 2a).
Additionally, binding could be blocked by pre-incubation with the
parentcompoundandsilverstainingofthegelshowedequalloading
of BTK protein (Supplementary Fig. S1). These results clearly con-
firmed the covalent binding property of Ibrutinib-BFL toward puri-
fied BTK.
Figure 1 | Structure and Synthetic Scheme of Ibrutinib-BFL (7). a. Crystal structure prediction of Ibrutinib-BFL (7) in its binding pocket of BTK. The
reactive cysteine is highlighted in yellow inside the box. Hydrogen bonds are shown as purple dotted lines. 3D models were rendered using PyMol.
b. Synthetic scheme of Ibrutinib-BFL (7).
www.nature.com/scientificreports
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firstdeterminedBTKexpressioninseverallymphomacelllines(Daudi
Burkitt’s Lymphoma line, and DB, Toledo, and RC-K8 Diffuse Large
B-Cell Lymphoma (DLBCL) lines) and one T-cell leukemia line
(Jurkat)byWesternblot(SupplementaryFig.S1).Asexpected,Tcells
did not express BTK. We found high BTK expression in Daudi and
Toledo cell lines, and henceforth used Toledo as model BTK-positive
cells and Jurkat as negative control cells. Toledo and Jurkat cells were
incubated with different doses of Ibrutinib-BFL, and cell lysates were
processed for SDS-PAGE and analyzed by fluorescent gel scanning.
The imaging probe showed remarkable specificity, with binding
observed only at a single band (Fig. 2b). The specificity was further
confirmedbytheabsenceofabandinBTK-negativeJurkatcells,even
at the highest concentration of probe (Fig. 2b), as well as by silver
staining of the gel (Supplementary Fig. S1).
We next performed live cell imaging experiments using an
imaging flow cytometry system. To prepare Toledo and Jurkat cells,
we incubated them with 100 nM Ibrutinib-BFL for two hours, fol-
lowed by washing. Figure 3 and Supplementary Fig. S2 summarize
some of the results confirming target binding, specificity via block-
ing, and the ability to perform live cell imaging. To quantify co-
localization between the imaging probe and BTK at the subcellular
level, we created a stable transgenic cell line expressing a BTK-
mCherry fusion protein in HT1080 human fibrosarcoma cells. In
vitro cell experiments showed excellent co-localization and blocking
(r
2 5 0.9851; Fig. 4).
We next performed in vivo experiments using three-color (blue:
vasculature,green:Ibrutinib-BFL,red:BTK-mCherry-HT1080cells)
time-lapseintravitalimaging.Theintravascularhalf-lifeofIbrutinib-
BFLwas,10minutes(SupplementaryFig.S3).Withinanhourafter
systemicadministration,therewasextensiveleakageofthecompound
into the tumor interstitium. At later time points, cellular uptake
becameapparent,presumablyduetointerstitialwashoutand/orintra-
cellular accumulation. The ability to image in multiple channels
allowed us to ask whether Ibrutinib specifically localized in tumor
cells. We show that greater than 99% of all BTK-mCherry-HT1080
cells had achieved therapeutic drug concentrations within one hour.
Thiseffectiveintracellulardosepersistedforprolongedperiodsoftime
and the compound was still detectable inside cancer cells 24 hours
after administration (Fig. 5). Interestingly, there was also accumula-
tion of Ibrutinib-BFL in non-tumor cells even at late time points.
Giventheexquisitespecificityofthedrug(seeFig.2),wehypothesized
that these non-target cells also contain BTK. We thus performed
correlative immunohistochemistry using anti-BTK antibody. Our
data indicates that Ibrutinib-BTK also accumulates in tumor-assoc-
iated macrophages and lymphocytes (Fig. 6).
Discussion
Inhibition of BTK is emerging as apromising target for B-cell malig-
nancies, other cancers with BTK over-expression, and certain auto-
immune diseases where BTK is involved. Ibrutinib, an irreversible
inhibitor, is approved for treatment of mantle cell lymphoma and
CLL, and is currently undergoing late-stage efficacy studies in
patientswithvariousB-cellmalignancies.Basedonitscovalenttarget
binding, we hypothesized that the molecule could serve as a com-
panion imaging agent. Here we show that this is indeed the case.
Ibrutinib-BFL co-localized with BTK in BTK-positive malignant
cells and had low background accumulation in non-BTK cells,
including those expressing structurally related interleukin-2-indu-
cible T-cell kinase (ITK), which is expressed in T cells and Jurkat
cells (see Supplementary Fig. S1). The companion imaging drug,
Ibrutinib-BFL, also showed a predictable dose response curve, could
becompetitivelyinhibited,alloweddrugconcentrationstobequanti-
tated in vivo, and enabled mapping of drug distributions at the single
cell level. As such, we believe that Ibrutinib-BFL could have several
applications, including use as a companion diagnostic for flow cyto-
metry in haematologic malignancies, as an imaging agent to localize
andmapBTK-positivetumors,asamethodtotracksubcellularlocal-
ization of endogenous BTK, and as a tool to measure pharmacoki-
netics and pharmacodynamics in experimental settings during
development of novel BTK-pathway inhibitors.
BTK is a cytoplasmic tyrosine kinase belonging to the Tec family.
It is expressed in the B-cell lineage, plays a pivotal role in signaling
and development, and is highly active in several haematological
malignancies
28,29. Some previous BTK imaging has been done with
fluorescent protein tags (BTK-GFP and BTK-mCherry) to under-
standitsactivationandnucleocytoplasmicshuttling
30–32,anditsroles
in myeloid cell chemotaxis
33 and infection
34,35. Alternative research
methods have primarily involved fluorescently labeled antibodies
for immunohistochemistry and flow cytometry applications. The
Figure 2 | Characterization. a. Target binding. Denaturing gel electrophoresis of decreasing concentrations of Ibrutinib-BFL incubated with 0.1 mg
purified BTK for onehour, imagedwith 488 nmexcitation/520 nm emission. Note the dose dependent binding ofIbrutinib-BFL. Size marker onthe far
left. b. Denaturing gel electrophoresis of cell lysates following incubation of decreasing concentrations of Ibrutinib-BFL with Toledo (BTK1, left half of
gel) or Jurkat (BTK-, right half of gel) cells at 37uC for two hours. Note the superb specificity of the probe.
www.nature.com/scientificreports
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expression, and the latterrequires cell permeabilization and fixation.
The approach developed here, utilizing a small molecule affinity
ligand, is compatible with live cells, can be used in vivo, and has
potential clinical applicability. Not only does Ibrutinib-BFL specif-
ically bind to BTK, but also it remains bound until protein turnover
due to the virtually nonexistent off-rate of covalent inhibitors. This
feature will allow for long-term study of endogenous BTK in live
cells, providing a window into drug pharmacodynamics, as well as
innate heterogeneity in responses to drugs targeting the BCR signal-
ing pathway
24,27.
Beyond utilizing Ibrutinib-BFL in pharmacologic studies of next
generation inhibitors, there are future diagnostic opportunities in
which BTK-expressing lymphomas could be imaged in the clinic.
While the current work focused on single cell imaging in vivo,w e
also anticipate whole body imaging applications. For example, the
fluorineinBODIPY-FLcouldbeexchangedfor
18Fforpositronemis-
siontomography(PET)imaging,orentirelyreplacedviabioorthogo-
nal ligands or direct
18F attachment
36–39. Alternatively, longer-lived
isotopes such as Zirconium-89 could also be utilized in order to take
full advantage of the probe’s irreversible binding kinetics
40–44.S u c h
moleculesmaybeusefulinclinicalimaging-basedtestsforwholebody
distribution and inhibition of BTK. Other areas of interest are to use
these molecules for imaging BTK in macrophages during infection, or
tousethemasareadoutduringgenetherapyfortheimmunodeficiency
disorder X-linked agammaglobulinemia, which results from loss of
functional BTK
45. Irrespective of the contemplated use, we believe that
the developed agent should be useful in a number of different applica-
tions.Ascovalentinhibitorshavegainedinterest,weanticipatecovalent
imagingagentstofollow,andIbrutinib-BFLcanprovidearoadmapfor
such development.
Methods
Synthesis and Characterization of Probe. All reagents were obtained from
commercial sources and used without further purification. Dry THF, MeOH, DCM,
and DMF were obtained from Sigma-Aldrich (St. Louis, MO).
1Ha n d
13C NMR
spectra were recorded at 23uC on a Bruker 400 MHz spectrometer. Recorded shifts
are reported in parts per million (d) and calibrated using residual undeuterated
solvent. Data are represented as follows: chemical shift, multiplicity (s 5 singlet,
d5doublet,t5triplet,q5quartet,p5pentet,m5multiplet,br5broad),coupling
constant (J, Hz), and integration. LC-ESI-MS analysis and HPLC-purifications were
performed on a Waters (Milford, MA) LC-MS system. For LC-ESI-MS analyses, a
WatersXTerraHC185 mmcolumnwasused.Forpreparativeruns,anAtlantisHPrep
T3 OBDTM 5 mm column was used [eluents 0.1% TFA (v/v) in water (solution A)
and MeCN (solution B); gradient: 0–1.5 min, 5–100% B; 1.5–2.0 min, 100% B for
analysis and 0–0.75 min, 5% B; 0.75–9.0 min, 5–100% B; 9.0–10.0 min, 100% B for
prep.].
3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1). A solution of 4-amino-1H-
pyrazolo[3,4-d]pyrimidine (780 mg, 5.77 mmol) and N-Iodo-succinimide (2.02 g,
8.98 mmol) in DMF (6 mL) was stirred at 80uC overnight. Resulting brown solution
was filtered and sticky solid was washed with water and cold ethanol. Resulting light
yellow solid was dried in vacuo to give compound 1 (1.50 g, 99.6% yield). Crude
product was used for the next reaction without further characterization.
Figure 3 | Cellular imaging of lymphoma cells. Representative images of Toledo (BTK-positive; left) and Jurkat (BTK-negative; right) cells incubated
with 100 nM Ibrutinib-BFL at 37uC for 2 hours, then in probe-free media at 37uC for 24 hours. Cells were co-stained with Hoechst (nucleus) and
CD45 (cell membrane) to show Ibrutinib-BFL localization in the cytoplasm of BTK-positive cells. Note the specificity. Images were obtained with an
Amnis ImageStream flow cytometry system.
www.nature.com/scientificreports
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compound 1 (200 mg, 0.77 mmol), tetrakis-(triphenylphosphine)palladium
(124 mg, 0.11 mmol), potassium phosphate tribasic (488 mg, 2.3 mmol), and 4-
phenoxyphenylboronic acid (492 mg, 2.3 mmol) in 1,4-dioxane (2.5 mL) in a
microwave vial was heated to 180uC for 10 minutes under microwave irradiation.
Resultingreactionmixturewasdilutedwithwaterandorganicmaterialwasextracted
with EA three times. Combined organic material was dried over Na2SO4 and
concentrated in vacuo. Resulting yellow solution was dissolved with DCM and
resulting turbid solution was filtered to give compound 2 as a white solid (138 mg,
59.4% yield).
1H NMR (400 MHz, DMSO) d 13.55 (s, 1H), 8.24 (s, 1H), 7.67 (d, J 5
8.2 Hz, 2H), 7.44 (t, J 5 7.8 Hz, 2H), 7.17 (m, 5H);
13C NMR (101 MHz, DMSO) d
158.0, 157.0, 156.3, 156.0, 155.7, 143.9, 130.1, 130.0, 128.4, 123.7, 119.0, 118.9, 96.9;
LRMS (ESI) m/z calcd for C17H13N5O[ M 1H]
1 304.12, found 304.14.
(R)-tert-butyl 3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-
yl)piperidine-1-carboxylate(3).Asolutionofcompound2(57 mg,0.19 mmol),(S)-
3-hydroxy-N-Boc-piperidine (80 mg, 0.40 mmol), DIAD (150 mL, 0.764 mmol),
and polymer-TPP (0.5 g, 1.6 mmol) in THF (4 mL) was stirred at ambient
temperature overnight. After reaction completion, polymer-TPP was removed by
filtration, filtrate was concentrated in vacuo and purified with silica gel column
chromatography(EA5Hex505100toEAonly)togivecompound3(45 mg,48.7%
yield) as a clear oil.
1H NMR (400 MHz, CDCl3) d 8.37 (s, 1H), 7.65 (d, J 5 7.5 Hz,
2H),7.38(m,2H),7.19–7.12(m,3H),7.08(d,J58.6 Hz,2H),5.49(s,2H),4.84(dq,
J 5 10.4, 5.1, 4.3 Hz, 1H), 4.35 – 4.23 (m, 1H), 4.16 – 4.06 (m, 1H), 3.46 (t, J 5
11.5 Hz,1H),2.88(td,J512.3,2.8 Hz,1H),2.34–2.14(m,2H),1.96–1.85(m,1H),
Figure 4 | Imaging of adherent BTK-mCherry cells to determine co-localization with Ibrutinib-BFL. a. Imaging co-localization between 500 nM
Ibrutinib-BFL (green) and HT1080 cells stably transfected with BTK-mCherry (red), following a 2-hour incubation with Ibrutinib-BFL and then a 24-
hour incubation in probe-free media (top). Center: competitive inhibition with 1 mM Ibrutinib prior to Ibrutinib-BFL addition. Bottom: Ibrutinib-BFL
incubated with non-BTK expressing parent HT1080 cells. b. Note the exquisite co-localization. Scale bar: 50 mm.
Figure 5 | In vivo tumor imaging. Serial imaging before, and at 2, 5 and
24 hours after intravenous administration of Ibrutinib-BFL to a
representative mouse harboring a BTK-positive HT1080 tumor (red; first
column). Note extensive drug accumulation in all cells, persisting even at
the 24-hour time point. * Indicates accumulation in non-tumor cells (see
Fig. 6). Scale bar: 50 mm.
Figure 6 | Histology. To corroborate intravital serial imaging, tumors
were examined histologically. Anti-BTK staining showed BTK signal in
HT-1080-BTK-mCherry cells as expected, but also in tumor-associated
macrophages (white). These regions of drug accumulation correspond to
those seen by intravital imaging (* in Fig. 5). Scale bar: 10 mm.
www.nature.com/scientificreports
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13C NMR (101 MHz, CDCl3) d 158.5, 157.8, 156.4,
155.7,154.6,154.2,143.6,130.0,129.9,127.9,124.0,119.5,119.1,98.6,79.8,52.9,48.2,
44.0, 30.2, 28.4, 24.5. LRMS (ESI) m/z calcd for C27H30N6O3 [M1H]
1 487.24, found
487.25.
(E)-ethyl 4-((tert-butoxycarbonyl)amino)but-2-enoate (4). To a solution of NaH
(50 mg, 1.26 mmol) in THF (4 mL), stirred at 0uC, triethylphosphonoacetate
(374 mL) wasadded dropwise. After warmingup toambienttemperature,solutionof
N-Boc-2-aminoacetaldehyde (100 mg, 0.63 mmol) in THF (1 mL) was added.
Reaction mixture was stirred at ambient temperature. After reaction completion,
reaction mixture was diluted with water and organic material was extracted with EA
three times. Combined organic material was dried over Na2SO4 and concentrated in
vacuo. Reaction mixture was purified with silica gel column chromatography (EA 5
Hex505100toEAonly)togivecompound4(110 mg,76.4%yield)asaclearoil.
1H
NMR (400 MHz, CDCl3) d 6.88 (dt, J 5 15.7, 4.9 Hz, 1H), 5.91 (dt, J 5 15.6, 1.8 Hz,
1H), 4.81 (s, 1H), 4.16 (q, J 5 7.2 Hz, 2H), 3.89 (s, 2H), 1.42 (s, 9H), 1.26 (t, J 5
7.1 Hz,3H);
13CNMR(101 MHz,CDCl3)d166.2,155.7,144.9,121.4,79.9,60.5,41.4,
28.4, 14.3; LRMS (ESI) m/z calcd for C11H19NO4 [M1H]
1 230.13, found 230.15.
(E)-4-((tert-butoxycarbonyl)amino)but-2-enoic acid (5). A solution of compound
4 (110 mg, 0.48 mmol) and LiOH (168 mg, 2.4 mmol) in THF (3 mL) and water
(2 mL) was stirred at ambient temperature overnight. THF was evaporated and
resulting yellow aqueous solution was acidified with 1N HCl to pH 3. Organic
material was extracted with DCM three times. Combined organic material was dried
overNa2SO4andconcentratedinvacuo.Reactionmixturewaspurifiedwithsilicagel
column chromatography (MeOH 5 DCM 5 0 5 100 to 1 5 10) to give compound 5
(80 mg,82.9%yield)asawhitesolid.
1HNMR(400 MHz,CDCl3)d6.93(dt,J515.9,
4.7 Hz,1H),5.87(dt,J515.7,1.9 Hz,1H),4.73(s,1H),3.88(s,2H),1.39(s,9H);
13C
NMR(101 MHz,CDCl3)d170.9,155.8,147.4,120.8,80.2,41.5,28.5;LRMS(ESI)m/
z calcd for C9H15NO4 [M1H]
1 202.10, found 202.10.
(R,E)-tert-butyl (4-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-
d]pyrimidin-1-yl)piperidin-1-yl)-4-oxobut-2-en-1-yl)carbamate (6). A solution of
compound3(100 mg,0.21 mmol)in2 mLofTFAandDCMmixture(1535v5v)
was stirred at ambient temperature. After 30 minutes stirring, reaction mixture was
concentrated in vacuo. After azeotropic distillation with DCM and ACN three times,
crudeproductwasconcentratedinvacuo.ThencrudeproductwasdilutedwithDMF
(2.1 mL) to make 0.1 M solution. 650 mL of crude product solution in DMF was
mixed with compound 5 (16 mg, 0.078 mmol), HBTU (37 mg, 0.097 mmol), and
TEA (45 mL) in DMF (200 mL) and reaction mixture was stirred at ambient
temperature. Afterone hour,reaction mixturewasdirectlyloaded ontoaC18reverse
phasecolumnforpurification(Water5ACNw/0.1%Formicacid59555to05100)
to give compound 6 (25 mg, 67.8% yield) as a sticky solid.
1H NMR (400 MHz,
CDCl3) d 8.36 (d, 1H), 7.72 – 7.57 (m, 3H), 7.38 (t, J 5 7.8 Hz, 2H), 7.21 – 7.02 (m,
5H),6.65(t,J59.8 Hz,1H),5.75(brs,2H),4.94–4.74(m,1H),4.74–4.60(m,1H),
4.52 (d, J 5 13.0 Hz, 0.5H), 4.10 – 3.97 (m, 0.5H), 3.86 (d, J 5 13.2 Hz, 0.5H), 3.66
(dd, J 5 13.2, 10.4 Hz, 0.5H), 3.33 (t, J 5 12.0 Hz, 0.5H), 3.26 – 2.95 (m, 2H), 2.85 –
2.66 (m, 0.5H), 2.50 – 2.15 (m, 2H), 2.06 – 1.86 (m, 1H), 1.80 – 1.58 (m, 1H), 1.46 (s,
9H); LRMS (ESI) m/z calcd for C31H35N7O4 [M1H]
1 570.28, found 570.20.
(R,E)-3-(3-((4-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-
1-yl)piperidin-1-yl)-4-oxobut-2-en-1-yl)amino)-3-oxopropyl)-5,5-difluoro-7,9-
dimethyl-5H-dipyrrolo[1,2-c:29,19-f][1,3,2]diazaborinin-4-ium-5-uide (7). A
solutionofcompound 6(5 mg,0.009 mmol) in2 mL ofTFAand DCM mixture (15
3 5 v 5 v) was stirred at ambient temperature. After 30 minutes stirring, reaction
mixturewasconcentratedinvacuo.AfterazeotropicdistillationwithDCMandACN
for three times, crude product was concentrated in vacuo. Then crude product was
dilutedwithDMF(880 mL)tomake0.1 Msolution.390 mLofcrudeproductsolution
in DMF was mixed with BODIPY-FL-NHS (1 mg, 0.0026 mmol) and TEA (2 mL,
0.013 mmol) in DMSO (1 mL) and the resulting reaction mixture was stirred at
ambient temperature for one hour and was then purified using standard HPLC
techniques to give compound 7 (1.1 mg, 57.6% yield) as a greenish solid.
1H NMR
(400 MHz, CDCl3) d 8.45 (br s, 1H), 8.23 (d, J 5 9.9 Hz, 1H), 7.63 (dd, J 5 32.3,
8.2 Hz,2H),7.48-7.21(m,3H), 7.21-7.06(m,2H),7.04-6.86(m,2H),6.66(dt,J5
4.9, 4.9, 15.3 Hz, 1H), 6.52 - 6.28 (m, 2H), 6.18 (d, J 5 22.1 Hz, 1H), 4.56 (d, J 5
12.3 Hz,1H),4.24(dd,J513.3,39.5 Hz,2H),4.03-3.78(m,3H),3.54-3.44(m,1H),
3.27-3.07(m,3H),2.74-2.62(m,1H),2.60-2.30(m,5H),2.29-2.17(m,3H),2.09-
1.99 (m, 1H), 1.74 - 1.60 (m, 1H); LRMS (ESI) m/z calcd for C40H40BF2N9O3
[M1H]
1 744.34, found 744.30.
CellLines.ThediffuselargeB-celllymphoma(DLBCL)celllinesDBandToledowere
generously provided by Dr. Anthony Letai (Dana Farber Cancer Institute, Boston,
MA, USA). The RC-K8 DLBCL cell line was a generous gift from Dr. Thomas
Gilmore (Boston University, Boston, MA, USA). Daudi Burkitt’s lymphoma cell line
and Jurkat T-cell leukemia line were from ATCC (Manassas, VA, USA). Lymphoma
cell lines were cultured in RPMI 1640 media supplemented with 10% fetal bovine
serum at 37uC and 5% CO2. To test the BTK inhibitor in adherent cells, we used
HT1080 human fibrosarcoma cells, which havepreviouslybeen shown tobe idealfor
intravital imaging studies
46. HT1080 cells were from ATCC, grown in DMEM
supplemented with 10% fetal bovine serum and 2% glutamine-penicillin-
streptomycin at 37uC and 5% CO2. HT1080-BTK-mCherry cells were prepared by
viral infection of HT1080 cells. Virus generated from pMSCVpuro-mCherry-BTK
retroviralvector
35wasagenerousgiftfromDr.HiddePloegh(MassachusettsInstitute
of Technology, Cambridge, MA, USA). Viral supernatant was added directly to
HT1080 cells for 48 hours, and BTK-mCherry-expressing cells were then selected
with RPMI media containing 2 mg/mL puromycin for 96 hours. Following selection,
HT1080-BTK-mCherrycells werecultured under the same conditions as the original
HT1080 cells.
Gel Electrophoresis. To test the covalent binding of Ibrutinib-BFL to BTK, 0.1 mg
(1 mL) purified BTK was combined with 0.4 mL Ibrutinib-BFL (prepared in advance
in 2-fold dilutions ranging from 200 mM to 0.19 mM, 33% DMSO in PBS) and
18.6 mL PBS, and incubated in the dark at room temperature for one hour. In the
secondexperiment,ToledoandJurkatcells(2.2310
6perwellinculturemedia)were
incubatedingrowthmediacontaining5-foldserialdilutionsofIbrutinib-BFLranging
from6 mMto9.6 nMinfinal2%DMSOat37uCfortwohours.Controlsampleswere
incubated in growth media containing 2% DMSO. Cells were washed once with ice
cold PBS, then lysed in 150 mL 1X RIPA buffer (Cell Signaling Technology, Beverly,
MA, USA) containing protease inhibitors. To the purified enzyme samples or cell
lysates, NuPAGE LDS sample buffer and NuPAGE reducing agent (Invitrogen) were
addedforfinal25%and10%concentrations,respectively,andsampleswereheatedto
70uC for 10–12 minutes in a Mastercycler thermal cycler (Eppendorf, Hamburg,
Germany). 25 mL per lane was loaded into 12-well NuPAGE Novex 4–12% Bis-Tris
gels (Invitrogen). Using 10 mL of Novex Sharp Pre-stained Protein Standard
(Invitrogen) as a sizemarker, the gels were runin NuPAGE MES SDS running buffer
(Invitrogen) at 200 V for 35 minutes in the XCell SureLock Mini-Electrophoresis
system (Invitrogen). The gels were removed from the cassette and imaged using a
Typhoon 9410 fluorescence scanner (GE Healthcare, Pittsburgh, PA, USA) using
488 nm excitation and a 520 nm emission filter. To show total protein loading, gels
were silver-stained using the Pierce Silver Stain for Mass Spectrometry kit (Thermo
Fisher Scientific, Rockford, IL, USA).
Imaging of non-adherent lymphoma cells by flow cytometry. Jurkat and Toledo
cellswere single-ortriple-stained withthe following,followedbywashing: Ibrutinib-
BFL (2 hours in growth media, 37uC), Hoechst 33342 nuclear dye (Invitrogen), or
APC-conjugated anti-human-CD45 antibody (Clone HI30, BioLegend, San Diego,
CA, USA)(both 30 minutes in PBS containing 2% BSA, 4uC). Stained cells were
transferred to Clear-view Snap-Cap microtubes (Sigma-Aldich) for Amnis
ImageStream
X Mark II imaging flow cytometry (Amnis Corporation, Seattle, WA,
USA). Single-stained samples were used to create a compensation table, then 30,000
imagesfromeachtriple-stainedsamplewerecollectedusingexcitationlasers405-nm,
488-nm, 592-nm, and bright-field excitation, and 430-550-nm (Ch7), 480-560-nm
(Ch2), 640–745-nm (Ch11), and 430–480 (Ch1) emission filters. Representative
images were manually selected from this data set.
Imaging of adherent cells by microscopy. HT1080-BTK-mCherry cells were seeded
into a 96-well plate at 20,000 cells per well and allowed to grow to confluence
overnight. Cells were incubated in growth media containing 1 mM Ibrutinib in final
0.1%DMSO, orcontrol0.1%DMSO, at37uCfor 1.5 hours. Withoutwashout,a 503
stock of Ibrutinib-BFL in 5% DMSO was added for a final concentration of 500 nM.
Control wells contained equivalent DMSO without Ibrutinib-BFL. Cells were
incubated for one hour at 37uC and then washed once with media for five minutes.
Themediawasthenreplacedandcellswereincubatedovernightat37uC.Thelivecells
were subsequently imaged on the DeltaVision imaging system (Applied Precision, a
GE Healthcare Company). Images were processed with Fiji software, an open-source
version of ImageJ.
In vivo tumor imaging. Nu/nu mice were implanted with 2 3 10
6 HT1080-BTK-
mCherry cells into a dorsal skinfold window chamber (APJ Trading Company,
Ventura, CA, USA) according to established protocols
47 and according with
guidelines from the Institutional Subcommittee on Research Animal Care. Tumors
were allowed to grow and vascularize for two weeks. 75 nmol Ibrutinib-BFL in
150 mL solution containing DMAc and solutol was injected via tail vein as reported
previously
48. Mice were anesthetized with 2% isoflurane in 2 L/min oxygen. Time-
lapsemicroscopywasperformed fortwo hours using a customized OlympusFV1000
confocal/multiphoton microscope equipped with a 203 objective (both Olympus
America, Chelmsford, MA, USA). In addition, tumors were imaged before injection,
and at 2, 5, and 24 hours post-injection. Images were processed with Fiji software.
Histology. HT1080-BTK-mCherry tumors were harvested from nu/nu mice and
embedded in O.C.T. compound (Sakura Finetek, Torrance, CA, USA). Serial 6 mm-
thick frozen sections were prepared for histological analysis. Fluorescence
immunohistochemistry staining was performed using Mac-3 (clone: M3/84, BD
Biosciences, San Jose, CA, USA) and BTK (clone: D3H5, Cell Signaling Technology),
followed by Alexa Fluor 647 goat anti-rat IgG and Alexa Fluor 488 goat anti-rabbit
IgG(bothInvitrogen)secondaryantibodies,respectively.Imageswerecapturedusing
a BX63 fluorescence microscope (Olympus America) equipped with a Neo sCMOS
camera (Andor Technology, Belfast, UK) and processed with Fiji software.
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